At last, the state of Indiana put out a useful tweet:
People with weakened immune systems are at greater risk if diagnosed with #COVID19, but there are treatments that can help prevent serious illness. Learn more at http://tinyurl.com/C19treatmentThe link goes to the state's page on COVID treatment, which includes the monoclonal antibody Sotrovimab. It's available, has emergency use authorization and effective against Omicron.
The clinical trial participants were at high risk of COVID progression due to age, obesity, diabetes and other risk factors. This was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
From the study:
In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P=0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively).
Evusheld (tixagevimab and cilgavimab) is also available as prophylaxis for moderately to severely immunocompromised people.Indiana's treatment website includes a map of treatment centers.
Comments